Targeting Multiple Myeloma Using B-Cell Maturation Antigens

BCMA is selectively induced at the time of plasma cell differentiation and is almost absent on immature and memory B cells (Avery et al., 2003; Chiu et al., 2007). The communication between BCMA and its ligand APRIL and BAFF is required for the maintenance of long-lived plasma cells (O'Connor et al., 2004; Peperzak et al., 2013).

BCMA is a perfect target for cancers of plasma cells as it is not present in other important organs. Dozens of BCMA-targeting therapies, such as antibody-drug conjugate, Bi-specific antibodies, and chimeric antigen receptor T (CAR-T) cells are presently being created and tested clinically. Bluebird and Celgene’s bb2121 is leading the pack. A phase I multi-center clinical trial has established a striking 80% response rate in multiple myeloma patients. If these methods are effectively established, it will bring multiple myeloma patients a much-needed option beyond Elotuzumab (anti-SLAMF7) and Daratumumab (anti-CD38antibody).

B-Cell Maturation Antigen (BCMA), a Target for Multiple Myeloma

The interactions between BAFF/APRIL and their receptors are selective. It should be noted that BCMA can interact with APRIL as well as BAFF (Bolkun et al., 2016). However, the affinity of APRIL-BCMA interaction is considerably higher when compared to BAFF-BCMA binding (Bossen and Schneider, 2006).

ACROBiosystems offers a wide-ranging panel of BCMA proteins, including the unique biotinylated BCMA (Cat. No. BC7-H82F0) and the monomeric BCMA (Cat. No. BCA-H522y). The company also provides-BCMA related proteins, for example, BAFF and BAFFR proteins.

Product Highlight

Immobilized Human BAFF, Fc Tag (Cat. No. BAF-H4268) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, Fc Tag (Cat. No. BC7-H82F0) with a linear range of 0.12–1.95 ng/mL.

Figure 1. Immobilized Human BAFF, Fc Tag (Cat. No. BAF-H4268) at 5 μg/mL (100 μL/well) can bind Biotinylated Human BCMA, Fc Tag (Cat. No. BC7-H82F0) with a linear range of 0.12–1.95 ng/mL.

The purity of Human BCMA, His Tag (Cat. No. BCA-H522y) is greater than 93% as determined by SEC-HPLC.

Figure 2. The purity of Human BCMA, His Tag (Cat. No. BCA-H522y) is greater than 93% as determined by SEC-HPLC.

ACROBiosystems provides a range of ready-to-use biotinylated proteins using their in-house developed labeling techniques, which offer high bioactivity and less batch-to-batch difference. Furthermore, they also provide FITC-labeled BCMA and BAFF proteins.

BCMA Product List

Molecule Cat. No. Species Structure
BCMA
(Biotin-labeled)
BC7-H82F0 BC7-H82F0-STC1
BCMA
(FITC-Labeled)
BCA-HF254 BCA-HF254-STC1
BCMA BCA-H522y BCA-H522y-STC1
BCMA BC7-H5254 BC7-H5254-STC1
BCMA
(Biotin-labeled)
BCA-M82F0 BCA-M82F0-STC1
BCMA
(Biotin-labeled)
BCA-M5258 BCA-M5258-STC1
BCMA
(Biotin-labeled)
BCA-C82F4 BCA-C82F4-STC1
BCMA BCA-C5253 BCA-C5253-STC1

Other Relevant Products

Molecule Cat. No. Species Structure
BAFF
(Biotin-labeled)
BAF-H82F3 BAF-H82F3-STC1
BAFF
(Biotin-labeled)
BAF-H82Q2 BAF-H82Q2-STC1
BAFF
(FITC-Labeled)
BAF-HF268 BAF-HF268-STC1
BAFF BAF-H4218 BAF-H4218-STC1
BAFF BAF-H4268 BAF-H4268-STC1
BAFF BAF-H5248 BAF-H5248-STC1
BAFF BAF-M5257 BAF-M5257-STC1
BAFFR
(Biotin-labeled)
BAR-M82F0 BAR-M82F0-STC1
BAFFR BAR-M5259 BAR-M5259-STC1
BAFFR BAR-H5257 BAR-H5257-STC1

Other Multiple Myeloma Targets

Molecule Cat. No. Species Structure
CD38
(Biotin-labeled)
CD8-H82E7 CD8-H82E7-STC1
CD38 CD8-H5224 CD8-H5224-STC1
SLAMF7
(Biotin-labeled)
SL7-H82E0 SL7-H82E0-STC1
SLAMF7 SL7-H5225 SL7-H5225-STC1
SLAMF7 SL7-H5256 SL7-H5256-STC1
 

References

  1. Avery et al., 2004, J Clin Invest. 112, 286–297.
  2. Chiu et al., 2007, Blood 109, 729–739.
  3. O’Connor et al., 2004, J. Exp. Med. 199, 91–98.
  4. Peperzak et al., 2013, Nat. Immunol. 14, 290–297.
  5. Bolkun et al., 2016, J. Cancer 7, 1979–1983.
  6. Bossen and Schneider, 2006, Semin. Immunol. 18, 263–275.

About ACROBiosystems

ACROBiosystems is an internationally recognized manufacturer of recombinant proteins committed to supporting cancer immunotherapy. We specialize in mammalian cell-based recombinant protein production and process development.

Our goal is to support professionals from pharmaceutical companies, CROs and research institutes who are working on the cancer immunotherapy area by providing high-quality proteins, antibodies and assay kits.

We have multiple offices and branches in North America, Europe, and Asia, and we are proud of serving customers from over 50 countries.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Aug 14, 2019 at 4:03 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2019, August 14). Targeting Multiple Myeloma Using B-Cell Maturation Antigens. News-Medical. Retrieved on August 19, 2019 from https://www.news-medical.net/whitepaper/20190814/Targeting-Multiple-Myeloma-Using-B-Cell-Maturation-Antigens.aspx.

  • MLA

    ACROBiosystems. "Targeting Multiple Myeloma Using B-Cell Maturation Antigens". News-Medical. 19 August 2019. <https://www.news-medical.net/whitepaper/20190814/Targeting-Multiple-Myeloma-Using-B-Cell-Maturation-Antigens.aspx>.

  • Chicago

    ACROBiosystems. "Targeting Multiple Myeloma Using B-Cell Maturation Antigens". News-Medical. https://www.news-medical.net/whitepaper/20190814/Targeting-Multiple-Myeloma-Using-B-Cell-Maturation-Antigens.aspx. (accessed August 19, 2019).

  • Harvard

    ACROBiosystems. 2019. Targeting Multiple Myeloma Using B-Cell Maturation Antigens. News-Medical, viewed 19 August 2019, https://www.news-medical.net/whitepaper/20190814/Targeting-Multiple-Myeloma-Using-B-Cell-Maturation-Antigens.aspx.

Other White Papers by this Supplier